Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... you’ll have a lot of winners with these drug and medical device plays.” For this article, we compiled ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

This has lagged the Medical sector's gain of 1. ... be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to be unveiled ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Eli Lilly (NYSE: LLY) sells a broad variety of drugs ... as declines in coronavirus testing hurt sales in diagnostics -- ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...